|
[1]MOOKERJEE RP, PAVESI M, THOMSEN KL, et al.Treatment with non-selective beta-blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure[J].J Hepatol, 2016, 64 (3) :574-582.
|
|
[2]BURROUGHS AK, THALHEIMER U.Hepatic venous pressure gradient in 2010[J].Hepatology, 2010, 51 (6) :1894-1896.
|
|
[3]RIPOLL C, GROSZMANN R, GARCIA-TSAO G, et al.Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis[J].Gastroenterology, 2007, 133 (2) :481-488.
|
|
[4]GE PS, RUNYON BA.The changing role of beta-blocker therapy in patients with cirrhosis[J].J Hepatol, 2014, 60 (3) :643-653.
|
|
[5]AL-GHAMDI H.Carvedilol in the treatment of portal hypertension[J].Saudi J Gastroenterol, 2011, 17 (2) :155-158.
|
|
[6]GLUUD LL, KRAG A.Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults[J].Cochrane Database Syst Rev, 2012, 15 (8) :cd004544.
|
|
[7]LO GH, CHEN WC, LIN CK, et al.Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding[J].Hepatology, 2008, 48 (2) :580-587.
|
|
[8]de FRANCHIS R, Baveno VI Faculty.Expanding consensus in portal hypertension:report of the Baveno VI Consensus Workshop:stratifying risk and individualizing care for portal hypertension[J].JHepatol, 2015, 63 (3) :743-752.
|
|
[9]VILLANUEVA C, ARACIL C, COLOMO A, et al.Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding[J].Gastroenterology, 2009, 137 (1) :119-128.
|
|
[10]HERNANDEZ-CEA V, ARACIL C, COLOMO A, et al.Development of ascites in compensated cirrhosis with severe portal hypertension treated with B-blockers[J].Am J Gastrocnterol, 2012, 107 (3) :418-427.
|
|
[11]ABRALDES JG, TARANTINO I, TURNES J, et al.Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis[J].Hepatology, 2003, 37 (4) :902-908.
|
|
[12]BOSCH J.Carvedilol for portal hypertension in patients with cirrhosis[J].Hepatology, 2010, 51 (6) :2214-2218.
|
|
[13]RERBERGER T, ULBRICH G, FERLITSCH A, et al.Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranol[J].Gut, 2013, 62 (11) :1634-1641.
|
|
[14]HOBOLTH L, MФLLER S, GRФNBK H, et al.Carvedilal or propranolal in portal hypertonsioa:a randomized comparison[J].Seand J Gastroenterel, 2012, 47 (4) :467-474.
|
|
[15]SINAGRA E, PERRICONE G, D'AMICO M, et al.Systematic review with meta-analysis:the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis[J].Aliment Pharmacol Ther, 2014, 39 (6) :557-568.
|
|
[16]LIN HC, YANG YY, HOU MC, et al.Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis[J].Am J Gastroenterol, 2004, 99 (10) :1953-1958.
|
|
[17]STANLEY AJ, DICKSON S, HAYES PC, et al.Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding[J].J Hepatol, 2014, 61 (5) :1014-1019.
|
|
[18]BHARDWAJ A, KEDARISETTY CK, VASHISHTHA C, et al.Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis:a randomised placebo-controlled trial[J].Gut, 2016.pii:gutjnl-2016-311735.
|
|
[19]MANDORFER M, PECK-RADOSAVLJEVIC M, REIBERGERT.Prevention of progression from small to large varices:are we there yet?An updated meta-anaylsis[J].Gut, 2016, 66 (7) :1347-1349.
|
|
[20]GE PS, RUNYON BA.Beta-blockers in cirrhosis:thank you for your attention[J].J Hepatol, 2014, 61 (2) :451-452.
|
|
[21]REIBERGER T, FERLITSCH A, PAYER BA, et al.Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis[J].J Hepatol, 2013, 58 (5) :911-921.
|
|
[22]MERLI M, LUCIDI, C, di GREGORIO V, et al.The chronic use of betablockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis[J].Liver Int, 2015, 35 (2) :362-369.
|
|
[23]BRITO-AZEVEDO A, PEREZ RDE M, COELHO HS, et al.Propranolol improves endothelial dysfunction in advanced cirrhosis:the'endothelial exhaustion'hypothesis[J].Gut, 2016, 65 (8) :1391-1392.
|
|
[24]USTUNDAG Y, SARITAS U.Non-selective beta-blockers for the patients with acute on chronic liver failure[J].J Hepatol, 2016, 65 (3) :645-649.
|
|
[25]REIBERGER T, FERLITSCH A, PAYER BA, et al.Non-selective beta-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis[J].J Gastroenterol, 2012, 47 (5) :561-568.
|
|
[26]MEHVAR R, BROCKS DR.Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans[J].J Pharm Pharm Sci, 2001, 4 (2) :185-200.
|
|
[27]WALLE T, WALLE UK, COWART TD, et al.Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects[J].Clin Pharmacol Ther, 1989, 46 (3) :257-263.
|
|
[28]CARDENAS A, MENDEZ-BOCANEGRA A.Report of the Baveno VI Consensus Workshop[J].Ann Hepatol, 2016, 15 (2) :289-290.
|
|
[29]ABBAS M, KHAN AM, RIFFAT S, et al.Assessment of sex differences in Pharmacokinetics of carvedilol in human[J].Pak J Pharm Sci, 2014, 27 (5) :1265-1269.
|
|
[30]OTEY CR, BANDARA G, LALONDE J, et al.Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450[J].Biotechnol Bioeng, 2006, 93 (3) :494-499.
|
|
[31]JOHNSON JA, HERRING VL, WOLFE MS, et al.CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences[J].J Pharmacol Exp Ther, 2000, 294 (3) :1099-1105.
|
|
[32]ZHANG F, DUAN X, ZHANG M, et al.Influence of CYP2D6andbeta2-adrenergic receptor gene polymorphisms on thehemodynamic response to propranolol in Chinese Han patients with cirrhosis[J].J Gastroenterol Hepatol, 2016, 31 (4) :829-834.
|
|
[33]SERSTE T, MELOT C, FRANCOZ C, et al.Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites[J].Hepatology, 2010, 52 (3) :1017-1022.
|
|
[34]MANDORFER M, BOTA S, SCHWABL P, et al.Nonselectiveβblockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis[J].Gastroenterology, 2014, 146 (7) :1680-1690.
|
|
[35]GARCIA-TSAO G.Beta blockers in cirrhosis:the window re-opens[J].J Hepatol, 2016, 64 (3) :532-534.
|
|
[36]GROSZMANN RJ, GARCIA-TSAO G, BOSCH J, et al.Betablockers to prevent gastroesophageal varices in patients with cirrhosis[J].New Engl J Med, 2005, 353 (21) :2254-2261.
|
|
[37]VILLANUEVA C, ALBILLOS A, GENESCA J, et al.Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension[J].Hepatology, 2015, 63 (1) :197-206.
|
|
[38]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Endoscopy, Chinese Medical Association.Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J].J Clin Hepatol, 2016, 32 (2) :203-219. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J].临床肝胆病杂志, 2016, 32 (2) :203-219.
|
|
[39]KALAMBOKIS GN, CHRISTODOULOU D, BALTAYIANNIS G, et al.Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites[J].Hepatology, 2016, 64 (5) :1806-1808.
|
|
[40]TURON F, CASU S, HERNNDEZ-GEA V, et al.Variceal and other portal hypertension related bleeding[J].Best Pract Res Clin Gastroenterol, 2013, 27 (5) :649-664.
|
|
[41]LEITHEAD JA, RAJORIYA N, TEHAMI N, et al.Non-selectiveβ-blockers are associated with improved survival in patients with ascites listed for liver transplantation[J].Gut, 2015, 64 (7) :1111-1119.
|
|
[42]BOSSEN L, KRAG A, VILSTRUP H, et al.Nonselectiveβ-blockers do not affect mortality in cirrhosis patients with ascites:Post Hoc analysis of three randomized controlled trials with 1198 patients[J].Hepatology, 2016, 63 (6) :1968-1976.
|
|
[43]LEE WG, MURPHY R, MCCALL JL, et al.Nadolol reduces insulin sensitivity in liver cirrhosis:a randomized double-blind crossover trial[J].Diabetes Metab Res Rev, 2017, 33 (3) :e2859.
|
|
[44] BAKRIS GL, FONSECA V, KATHOLI RE, et al.Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension:a randomized controlled trial[J].JAMA, 2004, 292 (18) :2227-2236.
|
|
[45]BASAT O, UCAK S, SEBER S, et al.After myocardial infarction carvedilol improves insulin resistance compared to metoprolol[J].Clin Res Cardiol, 2006, 95 (2) :99-104.
|
DownLoad: